Association of SOX11 gene expression withclinical features and prognosis of mantle cell lymphoma.

OBJECTIVE

To study the expression of SOX11 in the patients with mantle cell lymphoma (MCL) and explore the clinical values of SOX11 in MCL.

PATIENTS AND METHODS

In the paraffin-embedded MCL tissues of 75 patients diagnosed in the Department of Hematology, Shanxi Tumor Hospital, were performed the immunohistochemical labeling of Ki67 and SOX11 by the EnVision method. Meanwhile, the expression of SOX11 mRNA was also detected by reverse transcriptase-polymerase chain reaction (RT-PCR), and the association of SOX11 with such prognostic indexes as pathological typing, staging, immunophenotyping, and MIPI was analyzed using the statistical method.

RESULTS

The immunohistochemistry showed that 97% of cases expressed SOX11 positive, and the RT-PCR results showed that the expression of SOX11 mRNA in the MCL patients was significantly higher than those with reactive hyperplasia lymphoid [3.097 (1.311, 6.216) and 1.058 (0.302, 2.623, respectively (p<0.05). Higher expression of SOX11 mRNA was positively correlated with some good prognostic factors such as ECOG<2, no bone marrow involvement and low-risk according to the International Prognostic Index (IPI). The comparison of the survival curves between group SOX11 mRNA <M and SOX11 mRNA≥M showed the median survival in the former was shorter than that in the latter, which was 27 months and 50 months, respectively. There was a significant difference between the two groups.

CONCLUSIONS

The expression of SOX11 in MCL patients is significantly higher than normal controls, which can be used as a diagnostic index. Upregulated SOX11 may be a good prognostic factor in MCL patients.